Evidence-based recommendations for the practical use of anti-arrhythmic drugs and dronedarone in particular are published today on BJC online. The recommendations have been made in a consensus position statement by a multi-disciplinary expert group. The group was convened by Sanofi, the manufacturers of dronedarone, to address the need for guidance in the practical implementation of guidelines for anti-arrhythmic drugs. This follows the recent changes to European Medicines Agency and US Food and Drug Administration recommendations for dronedarone use.
Position statement on anti-arrhythmic drugs
May 2012 Leave a commentClick any image to enlarge
